What it is
BPC-157 is a short chain of 15 amino acids derived from a protein naturally found in human stomach juice. Researchers isolated the fragment they believed was responsible for the stomach lining's remarkable ability to protect and repair itself, and named it "Body Protection Compound."
It is not an approved drug anywhere in the world. In the research-peptide market it is sold as a material for laboratory study only. Almost everything known about it comes from cell and rodent experiments — there are, as of 2026, essentially no large, controlled human trials.
How it works
The leading theory is that BPC-157 promotes angiogenesis — the growth of new blood vessels — which brings more blood flow to an injured area and speeds repair. It appears to do this partly by boosting a growth-factor receptor pathway (VEGFR2) involved in blood-vessel formation.
Animal studies also suggest it interacts with the nitric oxide system (which controls blood-vessel dilation) and may modulate growth-factor signaling that tells cells to rebuild tissue. In plain terms: it seems to help the body's own repair crew show up faster and in greater numbers.
What people research it for
Faster tendon & ligament recovery
Animal studiesIn rats, BPC-157 accelerated healing of transected Achilles tendons and improved tendon-to-bone healing. This is the most-cited reason people in the research community are interested in it.
Gut protection
Animal studiesIts original research context was the digestive tract: it protected against and helped heal stomach and intestinal ulcers in rodents, and is studied in models of inflammatory bowel disease.
Muscle and soft-tissue repair
Animal studiesRodent studies show faster healing of crushed or torn muscle. Anecdotal human reports echo this, but anecdote is not controlled evidence.
What the research actually shows
The BPC-157 literature is large but almost entirely preclinical — cell cultures and rodents, much of it from a single research group in Croatia. Effects on tendon, ligament, muscle, gut, and even nerve healing have been reported repeatedly in animals.
The main human trial to watch is ClinicalTrials.gov NCT07437547, BPC 157 for Acute Hamstring Muscle Strain Repair. The record lists a recruiting, randomized, double-blind, placebo-controlled Phase 2 study from Hudson Biotech in 120 estimated adults ages 18 to 45 with MRI-confirmed acute grade II hamstring strain. Participants are randomized 1:1 to subcutaneous pentadecapeptide BPC 157 or matching placebo once daily for 14 days, with both groups following the same supervised rehabilitation program.
The co-primary endpoints are practical for recovery buyers: time to return to unrestricted sport over 8 weeks and change in MRI-assessed hamstring injury volume at day 14. Secondary measures include pain during activity, hamstring strength limb symmetry by isokinetic dynamometry, and Lower Extremity Functional Scale change through 56 days. The trial started February 2, 2026, has estimated primary completion on February 14, 2027, and has no posted results yet.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157 free base and BPC-157 acetate for inclusion on the Section 503A Bulks List. This was a non-binding advisory recommendation, not FDA approval or final placement on the list. For buyers, the practical quality checks remain the same: confirm exact BPC-157 identity, a batch-matched COA from a named lab, tested net content rather than purity alone, sterility and endotoxin results where available, and effective price per mg after discounts. Compare current offers on PeptidePub's BPC-157 price page and check vendor testing records before checkout.
That makes BPC-157 a promising trial-watch peptide, not a human-outcome lock. For buyers comparing vials today, the strongest move is still product proof: exact BPC-157 identity, lot-matched COA, net-content testing, named third-party lab, sterility and endotoxin checks when available, vendor transparency, and real price per mg after code before checkout.
Research handling & storage
BPC-157 is typically sold as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water for research use. Lyophilized peptide is usually stored refrigerated and, once reconstituted, kept cold and used within weeks.
A stabilized 'arginate' salt form is often marketed as more stable at room temperature than the acetate form. Purity and identity vary widely between vendors — which is exactly why third-party testing matters.
Safety & cautions
In animal studies BPC-157 has looked strikingly low-toxicity, with no consistent serious adverse effects reported. But 'safe in rats' is not 'safe in humans,' and there is no long-term human safety data.
Because it promotes blood-vessel growth, there is a theoretical concern about its effect on tumors, though this has not been demonstrated. It is banned by WADA for athletes. Anyone considering it should understand it is unapproved, unregulated, and unstudied in humans at scale.
Watch BPC-157 prices
We'll email you when prices drop, a discount code changes, or new lab results come in for BPC-157. No spam — only real changes.
Frequently asked questions
Is BPC-157 FDA approved?
No. BPC-157 is not approved as a drug or supplement by the FDA or any major regulator. In 2023 the FDA flagged it as a substance that poses risks when compounded. It is sold only as a research material.
Is there real human evidence for BPC-157?
Very little. The overwhelming majority of studies are in cells and rodents. Human evidence is essentially limited to anecdote and a small number of early investigations — not the large controlled trials needed to prove it works or is safe.
What is the BPC-157 hamstring trial?
NCT07437547 is a recruiting Phase 2 trial in 120 estimated adults with MRI-confirmed acute grade II hamstring strain. It compares BPC 157 with placebo for 14 days plus standardized rehabilitation, then measures return to unrestricted sport and MRI injury-volume change. No results are posted yet.
What do people research BPC-157 for?
Most interest centers on tendon, ligament, muscle, and gut healing, based on the animal literature. These are research interests, not proven human uses.
Why do prices and quality vary so much?
Because it is an unregulated research chemical, there is no manufacturing standard. Purity, identity, and sterility differ between vendors — the reason independent third-party testing (COAs) is the single most important thing to check before buying.
Sources
- Chang et al. — BPC-157 and tendon fibroblast healing (J Appl Physiol)
- Sikiric et al. — BPC-157 review of cytoprotection & angiogenesis
- ClinicalTrials.gov - NCT07437547 BPC 157 for Acute Hamstring Muscle Strain Repair
- FDA - July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
- Pharmaceutical Executive - July 23 PCAC vote results for BPC-157 and TB-500
- FDA — bulk drug substances nominated for compounding (Category 2 risk)
Last reviewed 2026-07-28. This guide is educational and research-focused — not medical advice. BPC-157 products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.
GO DEEPER
This guide covers one compound. We wrote the book on all 40.
The Peptide Handbook takes everything we know from testing vendors for a living and turns it into four readable books: what each compound actually does, what the evidence really says, and the honest call when the answer is "skip this one." Plus the dosing tables, calendars, and trackers that make it usable.
From the community
Ask a question →Related peptides
Ready to compare BPC-157?
See prices across trusted, third-party-tested vendors, normalized per milligram.
Compare BPC-157 prices →